

UTILITY PATENT APPLICATION TRANSMITTAL

(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BMID9967US

Total Pages in this Submission
92

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

DEOXYNUCLEOSIDE KINASE FROM INSECT CELLS FOR THE SYNTHESIS OF NUCLEOSIDE MONOPHOSPHATES

and invented by:

Hans-Georg IHLENFELDT, Brigitte MUNCH-PETERSEN, Jure PISKUR and Leif SONDERGAARD

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☐ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 20 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BMID9967US

Total Pages in this Submission
94

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets _____
- b. ☒ Informal Number of Sheets 8
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment (to follow)
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL315020693US

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BMID9967US

Total Pages in this Submission
92

Accompanying Application Parts (Continued)

15. ☒ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☒ Additional Enclosures (please identify below):

General Appointment of Representative for U.S. Patent and Patent Application (1pp).

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims		- 20 =	0	x \$22.00	\$0.00
Indep. Claims		- 3 =	0	x \$82.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$0.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$0.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
 - ☐ Credit any overpayment.
 - ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



Signature

Brent A. Harris, Reg. No. 39,215
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 576-3416

Dated: October 12, 1999


cc:

Deoxynucleoside kinase from insect cells for the synthesis of nucleoside monophosphates

The subject of the present invention is a recombinant kinase from insect cells such as e.g. *Drosophila Melanogaster*, remaining stable during the synthesis of nucleoside monophosphates without the addition of stabilizing SH reagents, without stabilizing proteins and detergents and accepting all four natural deoxynucleosides. A further subject matter of the present invention is a DNA sequence encoding the kinase according to the invention as well as a procedure for preparation of the kinase according to the invention and its use during the synthesis of nucleoside monophosphates.

(Deoxy)-nucleoside kinases catalyze the phosphorylation of nucleosides or deoxynucleosides, respectively, to the corresponding nucleotide monophosphates and have therefore an important role in the "salvage pathway" of the nucleotide metabolism.

The catalyzed reaction is:



The deoxynucleoside monophosphates are starting products for the deoxynucleoside triphosphates which are used to a very increasing extent as reagents for the PCR reaction.

The deoxynucleoside monophosphates are at present accessible by three ways:

1. from hydrolysis of fish sperm
2. by chemical synthesis from deoxynucleosides
3. by enzymatic synthesis from deoxynucleosides.

The hitherto known methods have a number of disadvantages. Thus, during the hydrolysis of fish sperm all 4 monophosphates are produced in about the same quantities; this is a fact that misses the requirements of the market (e.g. d-UTP, partially used instead of d-TTP is prepared from d-CTP). In addition, d-TTP, resulting from hydrolysis, is contaminated with approx. 2% d-UTP and can, practically, not be isolated.

Furthermore, the animal origin of the educts has to be assessed as critical from a regulatory point of view (GMP). Moreover, the market of monophosphates from fish sperm is very limited.

A number of side products are produced during the chemical synthesis which are difficult to separate by chromatographic purification. In addition, several bases (e.g. guanosine) must be provided with protective groups before phosphorylation which increases the synthesis time considerably.

The disadvantages of the state of the art were overcome by the provision of a recombinant multifunctional deoxynucleoside kinase from insect cells such as, in particular, *Drosophila melanogaster* (Dm-dNK) remaining stable during the synthesis of nucleoside monophosphates without the addition of stabilizing SH reagents, without stabilizing proteins and detergents and accepting all four natural deoxynucleosides: thymidine (dThd), deoxycytidine (dCyd), deoxyadenosine (dAdo) and deoxyguanosine (dGuo). In the present invention stable means that the yield rate for the catalyzed reaction does practically not decrease within 5 hours, preferably 10 hours, particularly preferably within 12 hours at 37°C. It is surprising that the enzyme remains

stable for such a long time without addition of stabilizers containing thiol. This stability has not been observed in other kinases until now (1-9). By leaving out these stabilizers when using the kinase according to the invention in the synthesis the synthesis gets cheaper and, above all, the product purification can be simplified to a great extent.

Furthermore, hitherto known kinases have a considerably higher substrate specificity; as a consequence, for the synthesis of the individual nucleosides it is no more necessary to have the corresponding specific kinase. Particularly advantageous is the low specificity for the synthesis of modified nucleoside analogues, such as dideoxynucleosides or base- or sugar-modified nucleosides. Base-modified nucleosides are for example 7-deaza-nucleosides, C-nucleosides and nucleotides labelled with reporter groups (dye, digoxigenin, biotin) at the base. Sugar-modified nucleosides are for example azathymidine, arabinosyl-thymidine. The kinetic constants of the *Drosophila* kinase compared to known analogous enzymes are listed in table 1. The specific activity k_c of the kinase according to the invention is several times higher than that of the kinases known before. The activity of the enzyme was measured as described in the reference: Munch-Peterson et al. (1991) *J.Biol.Chem.* 266, 9032-9038. By this, a considerably lower amount of enzyme is necessary to synthesize the dNMPs. (factor 3.5 – 14000, cf. K_c values in table 1). The specificity constant (k_c/K_M) of the kinase according to the invention exceeds that of the hitherto known kinases by several powers and is in the region of the diffusion constant. This leads to the complete yield when the kinase is added to the d-NMP synthesis. They are higher by factor 2-6500 than the hitherto known kinases, s. fig. 1.

Surprisingly, the enzyme according to the invention is still stable at 60°C what is advantageous for the reaction procedure. Preferably, the enzyme according to the invention has at $T=37^\circ\text{C}$ a half-life of $t_{1/2} \geq 50$ h in Tris buffer with 5 mM MgCl_2 and $t_{1/2} \geq 25$ h in water and accepts all natural deoxynucleosides (example 6).

A further subject matter of the invention are kinases from other non-vertebrate organisms, in particular from other animal species of the Hexapoda class showing comparable properties to those of the *Drosophila* kinase. Particularly such kinases essentially having the above described stability and the above described substrate specificity. Preferred kinases are those isolated from

the subclass of Pterygota and particularly preferable are those from the Diptera class, particularly preferable from the Drosophilidae family.

A further subject matter of the invention is a DNA sequence as well as functional fragments thereof coding for the kinase according to the invention. The DNA sequence according to the invention is characterized in that the primers listed in the following hybridize onto the DNA sequence of the kinase according to the invention:

SEQ ID No.: 2

GGGAAGTGGCAGGAGTAGCTCCCCG

SEQ ID No.: 3

CTCCCGTTGTAG**CCG**TCGCCCTTCTGG

SEQ ID No.: 4

GACGA**CT**GGCTCGGG**CAG**CTCTTCACCGCG**TTG**

SEQ ID No.: 5

TTCGATTTTTTATTACCTCGCGAGGTAA

SEQ ID No.: 6

AGGTAA**AAA**TCGCGAGCGATA**ACGA**AGCAC

SEQ ID No.: 7

CACCGCATGCTTGCGTAGGCCGTCGCCCCGAGCAAGACTCCTC

SEQ ID No.: 8

GACTACATGTTTCTAGGGTTCTTCACC

A further subject matter of the invention are also such kinases and DNA sequences onto the DNA sequence of which hybridize oligonucleotides with the SEQ ID No.: 2, 3, 5, 7 and 8 or with the SEQ ID No.: 2, 4, 5, 7 and 8 or with the SEQ ID No.: 2, 5, 6, 7 and 8.

The following hybridization conditions are advantageous:

- Hybridization: 0.75 M NaCl, 0.15 Tris, 10 mM EDTA, 0.1% sodium pyrophosphate, 0.1% SLS, 0.03% BSA, 0.03% Ficoll 400, 0.03% PVP and 100 µd/ml boiled calf thymus DNA at 50°C for approx. 12 hours.
- Washing: 3x30 minutes with 0.1 X SET, 0.1% SDS, 0.1% sodium pyrophosphate and 0.1 M phosphate buffer at 45°C

The kinase sequence according to the invention is given in fig. 5, SEQ ID No.: 1.

The DNA sequence according to the invention is obtainable from *Drosophila Melanogaster* by the procedure described in the following:

A pBluescript SK +/- phagmide containing a 1.1 kbp cDNA insert which contains among others the presumed gene coding for the deoxynucleoside kinase was obtained from the Berkeley *Drosophila* genome sequencing project (clone LD15983). The first 600 base pairs of the 5' end of the 1.1 kbp cDNA cloned via EcoRI and XhoI in the multiple cloning site (MCS) of the phagmide were already sequenced by Harvey et al., University of California, Berkeley. Based on these sequence information new primers were designed (Dm-TK1 and Dm-TK2/SEQ ID NO.9: 5'TCCCAATCTCACGTGCAGATC-3' and SEQ ID NO 10: 5'-TTCATCGAAGAGTCCATTAC-3' which enabled complete sequencing of the insert. Dm-TK1 is a 21 bp sense primer binding upstream from the presumed translation start region. Dm-TK2 was designed as 21 bp sense primer according to the 3' region of the cDNA part already sequenced.

With this sequence an open reading frame including 750 bp and coding for a protein with 250 amino acids could be identified. The DNA sequence SEQ ID NO.1 is depicted in figure 5. The calculated molecular weight of this protein was 29 kDa and corresponds therefore to the data given by Munch-Peterson et al. 1998 indicating a weight of nearly 30 kDa for native Dm-dNK.

Starting from the sequence information the structure gene coding for the Dm-dNK could be isolated from the 1.1 kbp cDNA insert of the pBluescript SK +/- phagmide by the "polymerase

chain reaction" technique (PCR) (Mullis, K.B. and Faloona, F.A., Methods in Enzymol. 155 (1987) 335-350). For this, a specific primer pair (see SEQ ID NO. 11: 5'-GCGCGAATTCATGGCGGAGGCAGCATCCTGTGC-3' and SEQ ID NO.12: 5'-GCGCAAGCTTATTATCTGGCGACCCTCTGGC-3') with the corresponding endonuclease restriction site of the later insertion into appropriate expression plasmids was synthesized. Thus, the 5'-primer (Dm-dNK3) has an EcoRI endonuclease restriction site upstream from the coding sequence whereas the 3'-primer (Dm-dNK4) contains a HindIII endonuclease restriction site downstream from the coding sequence. Furthermore, the 3'-primer contains downstream from to the coding sequence two stopcodons for safe termination of the translation. Further, suitable primers which were optimized for the translation initiation in *E. coli* were the following:

SEQ ID No.: 13 (Dm-dNK 3)

5'-CGCGAATTCA TGGCGGAAGC GGCGAGCTGC GCGCGTAAGG GGACC-3'

SEQ ID No.: 14 (Dm-dNK 4)

5'-CGCAAGCTTA TTAACGGGCG ACCCTCTGGC-3'

Cloning of the structure gene for the Dm-dNK in pUC18

The PCR preparation was applied to an agarose gel and the 750 Bp structure gene was isolated from the agarose gel. The PCR fragment was cut with the EcoRI and HindIII restriction endonucleases for 1 hour at 37°C. Simultaneously, the pUC18 plasmid was cut with the EcoRI and HindIII restriction endonucleases for 1 hour at 37°C, the preparation was then separated by agarose gel electrophoresis and the 2635 Bp vector fragment isolated. Subsequently, the PCR fragment and the vector fragment were ligated by T4-DNA-ligase. Then 1 µl (20 ng) of vector fragment and 3 µl (100 ng) of PCR fragment, 1 µl 10x ligase buffer (Maniatis et al., 1989 Molecular cloning, a laboratory manual, Sambrook, Fritsch, Maniatis, Book 3, Section B27; Munch-Peterson (1991) J. Biol. Chem. 266, 9032), 1 µl T4-DNA-ligase, 4 µl sterile H₂O bidist. were pipetted, carefully mixed and incubated over night at 16°C.

The cloned gene was checked by means of restriction analysis and by sequencing.

Cloning of the structure gene for the Dm-dNK in appropriate expression vectors

For expression of the Dm-dNK the structure gene was cloned in appropriate expression vectors in such a way that the structure gene is inserted in the right orientation under the control of an appropriate promoter, preferably an inducible promoter, particularly preferably the lac-, lacUV5-, tac- or T5 promoter. Preferred expression vectors are pUC plasmids with lac- or lacUV5 promoters or pKK plasmids.

For this, the structure gene was cut out of the plasmid pUC18 for the Dm-dNK by means of EcoRI and HindIII, the restriction preparation was separated by agarose gel electrophoresis and the approx. 750 Bp fragment was isolated from the agarose gel. Simultaneously, the expression vectors were cut with EcoRI and HindIII, the restriction preparation was separated by agarose gel electrophoresis and the resulting vector fragment was isolated from the agarose gel. The resulting fragments were ligated as described. The appropriate insertion of the gene was verified by restriction analysis and sequencing.

Preferred expression vectors are also pUC18, pKK177-3, pKKT5. Especially preferred is pKKT5. The expression vector pKKT5 is obtained from pKK177-3 (Kopetzki et al. 1989, Mol. Gen. Genet. 216:149-155) by exchanging the tac- promoters with the T5-promoter derived from the plasmid pDS (Bujard et al. 1987, Methods Enzymol. 155:416-433). The EcoRI-endonuclease restriction site was removed from the sequence of the T5-promotor by point mutation.

Transformation of the expression vectors in different E-coli expression strains

Competent cells of different E. coli strains were prepared according to the Hanahan method (J. Mol. Biol. **166** (1983) pp. 557). 200 µl of the resulting cells were mixed with 20 ng of isolated plasmid DNA (expression vectors). After 30 min. incubation on ice a thermal shock (90 sec. at 42°C) was carried out. Subsequently, the cells were transferred in 1 ml LB-medium and incubated for phenotypical expression for 1 hour at 37°C. Aliquots of this transformation pre-

paration were plated on LB plates with ampicillin as a selection marker and then incubated for 15 hours at 37°C.

Appropriate host cells are E. coli K12 JM83, JM101, JM105, NM522, UT5600, TG1, RR1ΔM15, E.coli HB101, E.coli B.

Expression of Dm-dNK in E.coli

For the expression of Dm-dNK clones containing plasmid were inoculated in 3 ml Lb_{amp} medium and incubated in the shaker at 37°C. At an optical density of 0.5 at 550 nm the cells were induced with 1mM IPTG and incubated in the shaker for 4 hours at 37°C. Subsequently, the optical density of the individual expression clones was determined. an aliquot with an OD_{550} of 3/ml was taken and the cells were centrifuged (10 min. at 6000 rpm, 4°C). The cells were re-suspended in 400 μ l TE buffer (50 mM TRIS/50 mM EDTA, pH 8.0), released by ultrasound and then the soluble protein fraction was separated from the insoluble protein fraction by centrifugation (10 min., 14000 rpm, 4°C). A buffer containing SDS and β -mercaptoethanol was added to all fractions and the proteins were denatured by boiling (5 min. at 100°C). Subsequently, each quantity of 10 μ l was analyzed by means of a 15% analytical SDS gel (Laemmli U.K. (1970) *Nature* 227: pp. 555-557).

A further subject matter of the invention is a method for production of the nucleoside monophosphates which is characterized in more detail by the following steps:

- Synthesis of the nucleoside monophosphates starting from nucleosides by enzymatic phosphorylation with a kinase according to the invention as an enzyme
- Use of a nucleotide triphosphate as a phosphate group donor in catalytic amounts
- In situ regeneration of the phosphate group donor via a regenerating system (CK/CP; PK/PEP; acetylphosphate/acylkinase, pyrophosphate/pyrophosphorylase)

As a nucleoside monophosphate according to the invention the original nucleoside monophosphates, deoxynucleoside monophosphates, dideoxynucleoside monophosphates as well as other sugar- and base-modified nucleoside monophosphates are applicable.

A further subject matter of the present invention is the use of the kinase according to the invention in the synthesis of the nucleoside monophosphate.

Brief description of the figures:

Figure 1:

The kinetic constants of different nucleoside kinases are listed in figure 1 (hTK1/2 = human thymidine kinase 1/2; hdCK=human deoxy-cytidine kinase; hdGK=human deoxy-guanosine kinase; HSV=Herpes Simplex Virus). The data are taken from:

- a) Munch Petersen et al. J. Biol. Chem. 266, 9032 (1991); J. Biol. Chem. 268, 15621 (1993),
- b) Biochem. Biophys. Acta 1250, 158 (1995),
- c) Bohmann and Eriksson Biochemistry, 27 4258 (1988),
- d) Wang et al. J. Biol. Chemistry 268, 22847 (1993),
- e) Iwatsuki et al. J. Mol. Biol. 29, 155 (1967),
- f) Black et al. J. Gen. Virology 77, 1521 (1996),
- g) Ma et al. P.N.A.S. 93, 14385 (1996).

Figure 2:

Figure 2 shows the formation of d-CMP from cytidine under the conditions mentioned in example 2.

Figure 3:

Figure 3 shows the formation of d-AMP from adenosine and d-GMP from guanosine under the conditions mentioned in example 4.

Figure 4:

Figure 4 shows the formation of d-CMP from cytidine under the conditions mentioned in example 3.

Figure 5:

Figure 5 shows the DNA sequence of the clone.

Figure 6:

Figure 6 shows the temperature optimum of the nucleoside kinase from *D. Melanogaster*.

Figure 7:

Figure 7 shows the stability of the recombinant Dm-nucleoside kinase compared to isolated Dm-nucleoside kinase. Figure 7A was determined without addition of BSA, fig. 7B with addition of BSA.

References

1. Lee, L.-S. and Y.-C. Cheng (1976) Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia, *J. Biol. Chem.*, 251, 2600-2604.
2. Cheng, Y.-C. and M. Ostrander (1976) Deoxythymidine kinase induced in HeLa TK cells by herpes simplex virus type I and type II. II. Purification and characterization. *J. Biol. Chem.*, 251, 2605-2610.
3. Ellims, P.H., T.E. Gan and L. Cosgrove (1982) Human thymidine kinase: Purification and some properties of the TK1 isoenzyme from placenta, *Mol. Cell. Biochem.*, 45, 113-116.
4. Gan, T.E., J.L. Brumley and M.B. Van Der Weyden (1983) Human thymidine kinase. Purification and properties of the cytosolic enzyme of placenta. *J. Biol. Chem.*, 258, 7000-7004.
5. Sherley, J.L. and T.J. Kelly (1988) Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells, *J. Biol. Chem.*, 263, 375-382.
6. Munch-Petersen, B., L. Cloos, G. Tyrsted and S. Eriksson (1991) Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides, *J. Biol. Chem.*, 266, 9032-9038.
7. Bohman, C. and S. Eriksson (1988) Deoxycytidine kinase from human leukemic spleen: Preparation and characterization of the homogenous enzyme. *Biochemistry*, 27, 4258-40265.
8. Kierdaszuk, B. and S. Eriksson (1990) Selective inactivation of the deoxyadenosine phosphorylating activity of pure human deoxycytidine kinase: Stabilization of different forms of the enzyme by substrates and biological detergents, *Biochemistry*, 29, 4109-4144.
9. Kristensen, T. Quantification of thymidine kinase (TK1) mRNA in normal and leukemic cells and investigation of structure-function relationship of recombinant TK1 enzyme. 1996.

Department of Life Sciences and Chemistry, Roskilde University, Denmark. Ref Type: Thesis/Dissertation. Available at Roskilde University Library.

10. Hanahan D., (1983) *J. Mol. Biol.* **166**: 557
11. Sambrook J., Fritsch E.F., Maniatis T., (1989) *Molecular cloning: A Laboratory Manual second Edition*, B.27 Cold Spring Harbor Laboratory Press NY (USA)
12. Mullis, K.B. und Faloona, F.A., (1987) *Methods in Enzymol.* **155**: 335-350
13. Munch-Peterson B., Piskur J. und Sondergaard L. (1998) *J. Biol. Chem.* **273**, 3926-3931
14. Laemmli U.K. (1970) *Nature* **227**: pp. 555-557

The invention is further explained by the following examples:

Example 1:

Production and isolation of the recombinant Dm kinase

An E. coli strain BL21 was transformed with a pGEX-2T vector (Amersham Pharmacia Biotec), in which the structure gene of the Dm kinase was cloned, by means of the CaCl_2 method (Sambrook, Molecular cloning, 2nd ed. Cold Spring Harbor Laboratory press). A transformed colony was suspended in 100 ml LB medium (10 mg tryptone, 5 mg yeast extract, 8 mg NaCl per l), containing 50 $\mu\text{g/ml}$ ampicilline, over night at 37°C. The next day, the culture was adjusted to an OD of 0.6 in 1 l of LB medium and the expression was induced by 100 μl IPTG. The culture temperature of 25°C was maintained over night and the cells were gathered by centrifugation. The cells were resuspended in 100 ml of buffer A (20 mM of potassium phosphate (pH 7.5), 5 mM MgCl_2 , 1 mM DTT, 10% glycerin, 1% Triton X100 and 0.1 mM phenylsulfonylfluorides). The mixture was broken up by the French press. The homogenized substance was centrifuged (20000 rpm/15 min.) and filtered with a 1 μm Whatman glass micro filter and a 0.45 μm cellulose acetate filter.

The homogenized substance was applied to a GSH column (15 x 45 mm), equilibrated with 10 column volumes of buffer B (140 mM NaCl, 2.7 mM KCL, 10 mM Na_2HPO_4 , 1.8 mM KH_2PO_4 , 1 mM DTT, 10% glycerol, 1% Triton X100, 0.1, mM phenylsulfonylfluoride, 5 mM benzamidine, 50 mM aminocaproic acid). The column was washed with 50 bed volumes of buffer B and 10 volumes of buffer C (140 mM NaCl, 2.7 mM KCl, 10 mM NaH_2PO_4 , 1.8 mM KH_2PO_4) and afterwards the fusion protein was split by recirculation of 1 column volume of buffer C with 400 U thrombin for 2 hours. The Dm-nucleoside kinase was then eluted with 3 column volumes of buffer C.

Example 2

Comparison of synthesis of d-CMP with and without thiol addition

d-Cyt	22 mg
Tris buffer pH 8.0	2 ml
MgAc	10 mg
ATP	66 mg
d-NK	0.132 U
DTT	7 mg/0 mg

The yield is determined by the integration of the peak areas using HPLC.

The reaction is not considerably slower in the preparation without DTT and is, above all, not terminated after 45 hours (see figure 2).

Example 3

Synthesis of d-GMP and d-AMP

d-Ado or d-Guo	28 mg
Water	2 ml
MgAc	32 mg
ATP	3 mg
CK	100 U
d-NK	0.396 U
CP (creatinphosphate)	20 mg

The reaction advances for 32 hours without slowing down, the yield rate is above 80% and no thiols must be added. The addition of Tris buffer is not absolutely necessary (see figure 3).

Example 4

Synthesis of d-CMP

d-Cyt	22 mg
Tris buffer pH 8.0	2 ml
MgAc	32 mg
ATP	3 mg
CK	100 U
d-NK	0.132 U
CP	20 mg

Even after 66 hours the enzyme is still active despite lacking thiol stabilizers. The yield rate is 80% despite the use of only catalytic ATP amounts (see figure 4).

Example 5

Synthesis of NMPs, dd-NMPs and base-modified d-NTPs

Substrate solution

CP	250 mg
ATP	7 mg
Mg acetate	160 mg

in 25 ml 50 mM Tris pH 8.0

An amount of each 0.5 ml of the solution is added to approx. 2.5 mg of the corresponding nucleoside. Then 50 U of the creatine kinase and 0.32 U of d-NK are added.

Preparation	Nucleoside	Time	Yield rate
a)	Cytidine	15 h	90%
b)	dd- adenosine	70 h	40%
c)	Iso-guanosine	2 h	80%

Example 6

Activity of the kinase from *D. Melanogaster* at different temperatures

The activity of the Dm-nucleoside kinase was determined at different temperatures. It shows a wide optimum with a maximum at 60°C (see figure 6).

The activity test is described in reference No. 14.

Example 7

Activity of the recombinant Dm-kinase compared to native Dm-kinase.

The activity of the recombinant Dm-kinase compared to native, isolated Dm-kinase was determined. After different periods of incubation in 50 mM Tris pH 7.5 + 2.5 mM MgCl₂ at 37°C the remaining activity was determined.

Whereas the recombinant Dm-kinase remains stable without the addition of BSA the activity of the native kinase decreases within 50 min to < 20%. By adding 2.5 mg/ml BSA the native kinase remains stable as well (fig. 7A + 7B).

The half-life in Tris buffer in the presence of MgCl₂ is 50 h, without MgCl₂ 31 h and in pure water 28 h. The native Dm-kinase has a half-life of <12 min. under the same conditions.

INFORMATION FOR SEQ ID NO. 9 (DM-dNK1)

SEQUENCE CHARACTERISTICS:

- (A) LENGTH : 21 base pairs
- (B) TYPE : nucleic acid
- (C) STRANDNESS : single
- (D) TOPOLOGY : linear

5'-TCCCAATCTCACGTGCAGATC-3'

INFORMATION FOR SEQ ID NO. 10: (DM-dNK2)

SEQUENCE CHARACTERISTICS:

- (A) LENGTH : 21 base pairs
- (B) TYPE : nucleic acid
- (C) STRANDNESS : single
- (D) TOPOLOGY : linear

5'-TTCATCGAAGAGTCCATTAC-3'

INFORMATION FOR SEQ ID NO. 11: (DM-dNK3)

SEQUENCE CHARACTERISTICS:

- (A) LENGTH : 33 base pairs
- (B) TYPE : nucleic acid
- (C) STRANDNESS : single
- (D) TOPOLOGY : linear

5'-GCGCGAATTCATGGCGGAGGCAGCATCCTGTGC-3'

INFORMATION FOR SEQ ID NO. 12: (DM-dNK4)

SEQUENCE CHARACTERISTICS:

- (A) LENGTH : 33 base pairs
- (B) TYPE : nucleic acid
- (C) STRANDNESS : single
- (D) TOPOLOGY : linear

5'-GCGCAAGCTTATTATCTGGCGACCCTCTGGC-3'

Claims

1. Recombinant kinase remaining stable during the synthesis of nucleoside monophosphate without the addition of stabilizing SH reagents, without stabilizing proteins and accepting all four natural deoxynucleosides, obtainable from cells of nonvertebrate organisms.
2. Recombinant kinase as claimed in claim 1 obtainable from insect cells.
3. Recombinant kinase as claimed in claim 1 or 2 showing - in a purified form - a specific activity of at least 20 U/mg (1U = 1 μ mol/min) for all 4 natural deoxynucleosides.
4. Recombinant kinase as claimed in one of the claims 1 to 3 showing a specificity constant k_c/K_m of $> 10000 \text{ M}^{-1} \text{ s}^{-1}$ for all natural deoxynucleosides.
5. Recombinant kinase as claimed in one of the claims 1 to 4 where the kinase has a half-life of $t_{1/2} \geq 50 \text{ h}$ in Tris buffer with 5 mM MgCl_2 and of $t_{1/2} \geq 25 \text{ h}$ in water at 37°C.
6. Recombinant kinase as claimed in one of the claims 1 to 5 showing a wide temperature optimum between 40 and 60°C.
7. Recombinant kinase as claimed in one of the claims 1 to 6, obtainable from *Drosophila Melanogaster*.
8. DNA sequence encoding a kinase from *Drosophila Melanogaster* as claimed in one of the claims 1 to 7.
9. DNA sequence as claimed in claim 8 wherein primers with the sequences SEQ ID No. 2 – 8 hybridize onto this DNA sequence.

10. Vector containing the DNA sequence as claimed in claim 8 or 9 and a promoter.
11. Host transformed with a vector as claimed in claim 10.
12. Method for production of a recombinant kinase as claimed in one of the claims 1 to 7, wherein the following steps are performed:
 - 1) isolation of the coding sequence of Dm-dNK,
 - 2) cloning of the structure gene in preferred expression vectors for E. coli with inducible promoters,
 - 3) transformation of the expression vectors in preferred E. coli host strains and
 - 4) expression of the Dm-dNK gene in E. coli by appropriate induction.
13. Use of a recombinant kinase obtainable from *Drosophila Melanogaster* as claimed in one of the claims 1 to 7 for the synthesis of the nucleoside monophosphate.
14. Method for production of a nucleoside monophosphate wherein a recombinant kinase as claimed in claims 1 to 7 is used for the phosphorylation of a nucleoside.

Abstract

Recombinant kinase remaining stable during the synthesis of nucleoside monophosphate without the addition of stabilizing SH reagents, without stabilizing proteins and accepting all four natural deoxynucleotides, obtainable from insect cells such as e.g. *Drosophila Melanogaster*. In addition, the invention concerns DNA sequences, vectors, transformed cells, a method for production of the recombinant kinase as well as its use for preparing nucleoside monophosphates.

Figure 1 Kinetic constants of deoxynucleoside kinases

		dThd	dCyd	dAdo	dGuo	ATP
Dm-dNK	k_c (1/s)	15	15	17,8	18,9	15
	K_m (μ M)	0,9	1	109	650	1
	k_c/K_m $M^{-1}s^{-1}$	$1,7 \times 10^7$	$1,5 \times 10^7$	$1,6 \times 10^5$	$2,9 \times 10^4$	$1,5 \times 10^7$
hTK1 (a)	k_c (1/s)	4,2				4,2
	K_m (μ M)	0,5				140
	k_c/K_m $M^{-1}s^{-1}$	$8,3 \times 10^6$				3×10^4
hTK2 (b)	k_c (1/s)	0,3	0,4			0,3
	K_m (μ M)	16	16			2
	k_c/K_m $M^{-1}s^{-1}$	$1,9 \times 10^4$	$2,5 \times 10^4$			$1,5 \times 10^5$
hdCK (c)	k_c (1/s)		0,073	0,31	0,4	0,073
	K_m (μ M)		1	120	150	10
	k_c/K_m $M^{-1}s^{-1}$		$7,3 \times 10^4$	$2,6 \times 10^3$	$2,7 \times 10^3$	$7,3 \times 10^3$
hdGK (d)	k_c (1/s)			$1,35 \times 10^{-3}$	$2,1 \times 10^{-3}$	
	K_m (μ M)			60	7,6	
	k_c/K_m $M^{-1}s^{-1}$			$2,3 \times 10^1$	$2,8 \times 10^2$	
E. Coli TK (e)	k_c (1/s)	1,6				1,6
	K_m (μ M)	9				500
	k_c/K_m $M^{-1}s^{-1}$	$1,8 \times 10^5$				$3,2 \times 10^3$
HSV TK (f)	k_c (1/s)	0,21				0,21
	K_m (μ M)	0,6				32
	k_c/K_m $M^{-1}s^{-1}$	$3,8 \times 10^5$				$6,6 \times 10^3$
Lactobac. dAK/dCK (g) or dGK	k_c (1/s)		0,91	0,05	0,7	0,91
	K_m (μ M)		4,5	8,4	7,8	1000
	k_c/K_m $M^{-1}s^{-1}$		2×10^5	6×10^3	$8,9 \times 10^4$	$9,1 \times 10^2$

Figure 2




Figure 3




Figure 4




Figure 5

Seq. ID No.: 1

ATG GCG GAG GCA GCA TCC TGT GCC CGA AAG GGG ACC AAG TAC GCC
GAG GGC ACC CAG CCC TTC ACC GTC CTC ATC GAG GGC AAC ATC GGC
AGC GGG
AAG ACC ACG TAT TTG AAC CAC TTC GAG AAG TAC AAG AAC GAC ATT
TGC CTG
CTG ACC GAG CCC GTC GAG AAG TGG CGC AAC GTC AAC GGG GTA AAT
CTG CTG
GAG CTG ATG TAC AAA GAT CCC AAG AAG TGG GCC ATG CCC TTT CAG
AGT TAT
GTC ACG CTG ACC ATG CTG CAG TCG CAC ACC GCC CCA ACC AAC AAG
AAG CTA
AAA ATA ARG GAG CGC TCC ATT TTT AGC GCT CGC TAT TGC TTC GTG
GAG AAC
ATG CGA CGA AAC GGC TCG CTG GAG CAG GGC ATG TAC AAT ACG CTG
GAG GAG
TGG TAC AAG TTC ATC GAA GAG TCC ATT CAC CTG CAG GCG GAC CTC
ATC ATA
TAT CTG CGC ACC TCG CCG GAG GTG GCG TAC GAA CGC ATC CGG CAG
CGG GCT
CGT TCT GAG GAG AGC TGC GTG CCG CTT AAG TAC CTT CAG GAG CTG
CAT GAG
TTG CAC CAG GAC TGG TTG ATA CAC CAG AGA CGA CCG CAG TCG TGC
AAG GTC
CTA GTC CTC GAT GCC GAT CTG AAC CTG GAA AAC ATT GGC ACC GAG
TAC CAG
CGC TCG GAG AGC AGC ATA TTC GAC GCC ATC TCA AGT AAC CAA CAG
CCC TCG
CCG GTT CGT GTG TCG CCC AGC AAG CGC CAG AGG GTC GCC AGA **TAA**

Figure 6




Figure 7A





Figure 7B



Docket No.
BMID9967US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

DEOXYNUCLEOSIDE KINASE FROM INSECT CELLS FOR THE SYNTHESIS OF NUCLEOSIDE MONOPHOSPHATES

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority	Not Claimed
198 46 838.5 (Number)	Germany (Country)	12 October 1998 (Day/Month/Year Filed)
199 14 644.6 (Number)	Germany (Country)	31 March 1999 (Day/Month/Year Filed)
 (Number)	 (Country)	 (Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Brent A. Harris, Reg. No. 39,215

D. Michael Young, Reg. No. 33,819

Richard T. Knauer, Reg. No. 35,575

Jill Lynn Woodburn, Reg. No. 39,874

Marilyn L. Amick, Reg. No. 30,444

Send Correspondence to: **Brent A. Harris**
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D, P.O. Box 50457
Indianapolis, IN 46250-0457

Direct Telephone Calls to: *(name and telephone number)*
Brent A. Harris, Telephone No. (317) 576-3416

Full name of sole or first inventor Hans-Georg IHLENFELDT	
Sole or first inventor's signature	Date
Residence Rabenkopfstr. 5, D-82393 Iffeldorf, Germany	
Citizenship German	
Post Office Address Rabenkopfstr. 5	
D-82393 Iffeldorf, Germany	

Full name of second inventor, if any Brigitte MUNCH-PETERSEN	
Second inventor's signature	Date
Residence Bavnebjergspark 36, DK-3520 Farum	
Citizenship Danish	
Post Office Address Bavnebjergspark 36	
DK-3520 Farum, Denmark	

Full name of third inventor, if any Jure PISKUR	
Third inventor's signature	Date
Residence Slovenian	
Citizenship Rudolph Bergsgade 22, DK-2100, Copenhagen, DK	
Post Office Address Rudolph Bergsgade 22	
DK-2100, Copenhagen, DK	

Full name of fourth inventor, if any Leif SONDERGAARD	
Fourth inventor's signature	Date
Residence Vangedevej 39, DK-2820 Gentofte, DK	
Citizenship Danish	
Post Office Address Vangedevej 39	
DK-2820 Gentofte, DK	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	